The Gastrointestinal Diseases Therapeutics Market is being driven by Increasing incidence of gastrointestinal diseases
The Gastrointestinal Diseases Therapeutics Market is expected to grow at a CAGR of 7.1% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 20683.2 million. In the realm of gastrointestinal diseases therapeutics, nutritional therapies hold considerable importance, offering effective management and enhancing the quality of life for patients. Particular gastrointestinal conditions, such as irritable bowel syndrome (IBS) and celiac disease, exhibit positive responses to dietary modifications. The guidance of healthcare providers and dietitians is essential for patients embarking on dietary adjustments. One notable dietary approach is the low-FODMAP diet, which restricts fermentable carbohydrates triggering IBS symptoms. The availability of certified low-FODMAP resources and food products significantly facilitates adherence to this diet. For individuals diagnosed with celiac disease or non-celiac gluten sensitivity, a strict gluten-free diet is mandatory. The significance of these dietary interventions underscores the need for continuous research and development in the gastrointestinal diseases therapeutics market.
Get more information on Gastrointestinal Diseases Therapeutics Market by requesting a sample report
The market is segmented based on
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
However, the market also witnesses some limitations, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
215 |
|
Base year |
2024 |
|
Historic period |
2019-2023 |
|
Forecast period |
2025-2029 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 7.1% |
|
Market growth 2025-2029 |
USD 20683.2 million |
|
Market structure |
fragmentation |
|
YoY growth 2024-2025(%) |
6.5 |
|
Key countries |
US, China, Canada, Germany, Japan, UK, India, France, Italy, and South Korea |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Find out which segment is leading the market by accessing the free PDF report
The Gastrointestinal (GI) Diseases Therapeutics Market encompasses treatments for various conditions, including gastroesophageal reflux disease, inflammatory bowel disease, irritable bowel syndrome, gastrointestinal cancers, autoimmune diseases such as Type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and specific GI disorders like Crohn's disease and ulcerative colitis. This market focuses on developing novel therapies and targeted drugs to address chronic digestive diseases.
The gastrointestinal diseases therapeutics market encompasses pharmaceutical companies and researchers involved in the development and production of both generic and non-generic drugs, as well as veterinary drugs. According to Technavio's market analysis, the global pharmaceuticals market size is determined by the collective revenue generated by manufacturers and providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Factors driving the growth of this market include the increasing global population aging, with the number of individuals over 60 years old in the US projected to reach nearly one-quarter by 2050, and Europe expected to reach a similar ratio by 2030. This demographic shift will lead to a higher prevalence of gastrointestinal diseases, including gastroesophageal reflux disease, inflammatory bowel disease, irritable bowel syndrome, gastrointestinal cancers, and autoimmune diseases, thereby fueling market expansion.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
